Our study found that canagliflozin, dapagliflozin, and empagliflozin were associated with significantly increased risk of genital infections compared with placebo and other active treatments. Only dapagliflozin had dose–response relationship with UTIs and genital infections (Diabetes, Obesity and Metabolism)
Diabetes News Service
Glycosmedia is also available as an App:
For iPhone and iPad | For Android devices
Sponsorship and Advertising
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
